Q2 2025 Management View Jason B. Few, President and CEO, announced a restructuring plan intended to prioritize sales of the ...

Objective The role of neutrophils in driving pathogenic B cell responses in SLE is not fully understood. In this study, we explored the link between immune complex (IC)–driven neutrophil activation, ...

Methods to probe the antigen-specific B cell response have advanced our understanding of how to harness the remarkable breadth of the B cell repertoire and the exquisite specificity of the individual ...

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...

Institute of Hybrid Materials, National Center of International Research for Hybrid Materials Technology, National Base of International Science & Technology Cooperation, College of Materials Science ...

Germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs) show dependence on DOT1L and EZH2, with combined targeting offering potential as an alternative differentiation-based therapy.

Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of non-Hodgkin's lymphomas and is a rare but aggressive form of T-cell lymphoma that usually occurs in children and young adults.

Earlier today, the company showcased case studies utilizing xPloration, a high-throughput single B-cell screening platform that harnesses machine learning and computer vision artificial ...

“Any drugs that could be able to do this could be game-changing.” B cell lymphoma 2 antagonist/killer (BAK) and B cell lymphoma 2-associated X protein (BAX) are BCL-2 family proteins that ...

Uppsala University Hospital was the first in Europe to initiate an academic CAR T study for patients with B-cell lymphoma. Five years later, in 2019, the first patient was treated within standard ...